<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03860558</url>
  </required_header>
  <id_info>
    <org_study_id>2015-40</org_study_id>
    <nct_id>NCT03860558</nct_id>
  </id_info>
  <brief_title>Impact of Metabolic Health on Sperm Epigenetic Marks in Humans</brief_title>
  <official_title>Impact of Metabolic Health on Sperm Epigenetic Marks in Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Joslin Diabetes Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Joslin Diabetes Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate whether epigenetic markers in overweight men with type 1&#xD;
      or type 2 diabetes can be improved with a 3 month lifestyle intervention or program focused&#xD;
      in glycemic intervention.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Parental history of type 2 diabetes (T2D) confers substantial individual risk for development&#xD;
      of obesity and diabetes. Obesity risk can be transmitted across generations, from parents or&#xD;
      grandparents to children. Genomic variation explains only a portion of this risk. Epigenetic&#xD;
      modulation through DNA methylation, histone modification, or by noncoding RNAs, provide&#xD;
      mechanisms to regulate gene activity independent of DNA sequence by determining which genes&#xD;
      are turned on or off in response to environment or disease. Epigenetic changes can be stable&#xD;
      over the lifespan providing a mechanism through which environmental exposures may impart&#xD;
      long-term effects on gene expression and phenotypic outcome.&#xD;
&#xD;
      The maternal intrauterine environment is now well recognized to modify obesity and T2D&#xD;
      disease risk of offspring. Fetuses carried by women who are obese, diabetic or suffer from&#xD;
      suboptimal nutrition are at increased risk of insulin resistance, obesity, T2D, and&#xD;
      cardiovascular disease risk as adults. Studies in rodents also show that the health,&#xD;
      metabolism, and prior environmental exposures of the male can also influence health of his&#xD;
      offspring. Existing data provide powerful support for the hypothesis that current metabolic&#xD;
      health of males can alter epigenetic marks in sperm and suggest a novel modifiable mechanism&#xD;
      of transmission. However, much less is known about how human sperm epigenetic patterns change&#xD;
      with nutritional and metabolic health, and whether these may ultimately impart differences in&#xD;
      health of future generations.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2018</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Spermatozoa concentration</measure>
    <time_frame>1 year</time_frame>
    <description>Sperm will be assessed for concentration, reported as total yield (millions per ml)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sperm DNA methylation, reported as genomic location of regions with methylation altered in response to intervention</measure>
    <time_frame>1 year</time_frame>
    <description>We will utilize purified DNA (1.5 Î¼g), sheared by sonication to obtain 200-700 bp fragments for subsequent library preparation for methylation-dependent immunoprecipitation and sequencing. Differentially methylated regions (DMR) are identified using MEDIPS. DNA methylation is assessed using sliding windows (500 bp size, 200 bp shift). Regions with read ratios &gt;1.5 or &lt;0.67 and binomial p&lt;0.0001 in independent biologically replicated comparisons are designated as DMR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RNA Sequencing</measure>
    <time_frame>1 year</time_frame>
    <description>RNA will be isolated from sperm samples and subjected to RNA sequencing to analyze the content of both of large mRNA/noncoding RNA and small RNAs. Data will be analyzed to identify those species altered in response to intervention.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Overweight</condition>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Type 1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Lifestyle Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 overweight men with T1D or T2D will undergo an intensive 3 month lifestyle intervention program aimed at improving metabolic health, glycemic control, and body weight.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No-Intervention Controls</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10 overweight men with T1D or T2D will be assessed at baseline and at 3 months. They will not participate in a lifestyle intervention.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Controls</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10 healthy men will be assessed at baseline and at 3 months. They will not participate in a lifestyle intervention.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Lifestyle Intervention</intervention_name>
    <description>Participants will undergo a 12-week multidisciplinary program for weight control and intensive diabetes management. The program includes adjustments to diabetes medications to enhance weight reduction and improve glycemia, dietary modification, and activity instructions.</description>
    <arm_group_label>Lifestyle Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No Intervention</intervention_name>
    <description>Participants will not undergo an intervention.</description>
    <arm_group_label>Healthy Controls</arm_group_label>
    <arm_group_label>No-Intervention Controls</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male, age 18-65 years&#xD;
&#xD;
          -  Willing and able to provide informed consent and follow all study procedures,&#xD;
             including providing sperm specimens 3 months apart.&#xD;
&#xD;
          -  Type 1 or type 2 diabetes diagnosis confirmed by an endocrinologist (for participants&#xD;
             in the diabetes groups)&#xD;
&#xD;
          -  HbA1c &gt; 7% (for participants in the diabetes groups)&#xD;
&#xD;
          -  Overweight (BMI &gt; 25 kg/m2) (for all groups, to ensure groups are similar)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Chronic kidney disease stage 4 or 5 (including end-stage renal disease);&#xD;
&#xD;
          -  Hepatic disease, including serum ALT or AST greater than or equal to 3 times the upper&#xD;
             limit of normal; hepatic synthetic insufficiency as defined as serum albumin &lt; 3.0&#xD;
             g/dL; or serum bilirubin &gt; 2.0;&#xD;
&#xD;
          -  Severe diabetic retinopathy;&#xD;
&#xD;
          -  Congestive heart failure, NYHA class II, III or IV;&#xD;
&#xD;
          -  History of myocardial infarction, unstable angina or revascularization within the past&#xD;
             6 months;&#xD;
&#xD;
          -  Active genitourinary infection;&#xD;
&#xD;
          -  Testicular volume &lt;12 mL (assessed using Prader orchidometer);&#xD;
&#xD;
          -  Hypogonadism, defined as total testosterone &lt;250 ng/dl;&#xD;
&#xD;
          -  Hyperprolactinemia, defined as prolactin &gt;18 ng/ml;&#xD;
&#xD;
          -  Hyperestrogenism, defined as estradiol &gt;42 pg/ml;&#xD;
&#xD;
          -  Cryptorchidism;&#xD;
&#xD;
          -  Cigarette smoking;&#xD;
&#xD;
          -  Active alcohol abuse or substance abuse;&#xD;
&#xD;
          -  Cancer (except localized non-melanoma skin cancers) or use of chemotherapy agents&#xD;
             within 5 years;&#xD;
&#xD;
          -  Use of nitrates or guanylate cyclase stimulators;&#xD;
&#xD;
          -  Use of steroid hormones (including testosterone), other than inhalers for reactive&#xD;
             airway disease&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mary E Patti, MD</last_name>
    <phone>6173092635</phone>
    <email>mary.elizabeth.patti@joslin.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elvira Isganaitis, MD</last_name>
    <email>elvira.isganaitis@joslin.harvard.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Joslin Diabetes Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary E Patti, MD</last_name>
      <phone>617-309-2635</phone>
      <email>mary.elizabeth.patti@joslin.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Elvira Isganaitis, MD</last_name>
      <email>elvira.isganaitis@joslin.harvard.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Mary E. Patti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elvira Isganaitis, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Sales VM, Ferguson-Smith AC, Patti ME. Epigenetic Mechanisms of Transmission of Metabolic Disease across Generations. Cell Metab. 2017 Mar 7;25(3):559-571. doi: 10.1016/j.cmet.2017.02.016. Review.</citation>
    <PMID>28273478</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>October 11, 2018</study_first_submitted>
  <study_first_submitted_qc>February 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 4, 2019</study_first_posted>
  <last_update_submitted>April 28, 2021</last_update_submitted>
  <last_update_submitted_qc>April 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

